Blueprint Medicines Corporation – NASDAQ:BPMC
Founder-led company
Blueprint Medicines stock price today
$129.46
+40.06
+44.81%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Blueprint Medicines stock price monthly change
-24.10%
month
Blueprint Medicines stock price quarterly change
-24.10%
quarter
Blueprint Medicines stock price yearly change
-3.71%
year
Blueprint Medicines key metrics
Market Cap | 5.66B |
Enterprise value | 2.41B |
P/E | -4.57 |
EV/Sales | 11.81 |
EV/EBITDA | -4.60 |
Price/Sales | 11.81 |
Price/Book | 4.68 |
PEG ratio | -0.33 |
EPS | -4.76 |
Revenue | 282.20M |
EBITDA | -434.55M |
Income | -288.28M |
Revenue Q/Q | 51.87% |
Revenue Y/Y | 37.93% |
Profit margin | -273.24% |
Oper. margin | -263.44% |
Gross margin | 91.27% |
EBIT margin | -263.44% |
EBITDA margin | -153.98% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBlueprint Medicines stock price history
Blueprint Medicines stock forecast
Blueprint Medicines financial statements
Average Price Target
$127
Potential downside: -1.90%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 57.57M | -132.79M | -230.66% |
|---|---|---|---|
| Sep 2023 | 56.56M | -133.71M | -236.38% |
| Dec 2023 | 71.95M | -110.91M | -154.14% |
| Mar 2024 | 96.11M | 89.13M | 92.74% |
| 2023-08-02 | -2.55 | -2.68 |
|---|
| Jun 2023 | 1106445000 | 795.31M | 71.88% |
|---|---|---|---|
| Sep 2023 | 1105299000 | 902.68M | 81.67% |
| Dec 2023 | 1049250000 | 918.64M | 87.55% |
| Mar 2024 | 1038474999 | 727.78M | 70.08% |
| Jun 2023 | -130.47M | 32.06M | 5.29M |
|---|---|---|---|
| Sep 2023 | -104.48M | -9.58M | 98.39M |
| Dec 2023 | -78.92M | 78.76M | 15.52M |
| Mar 2024 | -101.51M | 77.13M | 66.96M |
Blueprint Medicines alternative data
| Aug 2023 | 651 |
|---|---|
| Sep 2023 | 660 |
| Oct 2023 | 660 |
| Nov 2023 | 661 |
| Dec 2023 | 661 |
| Jan 2024 | 661 |
| Feb 2024 | 661 |
| Mar 2024 | 655 |
| Apr 2024 | 655 |
| May 2024 | 655 |
| Jun 2024 | 645 |
| Jul 2024 | 645 |
Blueprint Medicines other data
100.00%
0.00%
of BPMC is owned by hedge funds
235
-39
58.93M
-97.29K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 25000 |
| Feb 2024 | 0 | 5000 |
| Mar 2024 | 0 | 118534 |
| May 2024 | 0 | 55648 |
| Jun 2024 | 0 | 88149 |
| Jul 2024 | 0 | 12667 |
| Aug 2024 | 0 | 46322 |
| Sep 2024 | 0 | 19702 |
| Oct 2024 | 0 | 3633 |
| Nov 2024 | 0 | 29451 |
| Dec 2024 | 0 | 1819 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | HURLEY ARIEL officer: PRINCIPA.. | Common Stock | 1,600 | $15.01 | $24,016 | ||
Sale | HURLEY ARIEL officer: PRINCIPA.. | Common Stock | 1,200 | $92.88 | $111,456 | ||
Sale | HURLEY ARIEL officer: PRINCIPA.. | Common Stock | 619 | $93.99 | $58,180 | ||
Option | HURLEY ARIEL officer: PRINCIPA.. | Stock Option (Right to Buy) | 1,600 | $15.01 | $24,016 | ||
Sale | HAVILAND KATE officer: CHIEF EXECUTIVE OFFICER | Common Stock | 400 | $95.4 | $38,160 | ||
Sale | HAVILAND KATE officer: CHIEF EXECUTIVE OFFICER | Common Stock | 1,746 | $96.74 | $168,908 | ||
Sale | HAVILAND KATE officer: CHIEF EXECUTIVE OFFICER | Common Stock | 207 | $97.76 | $20,236 | ||
Sale | ROSSI CHRISTINA officer: CHIEF OPERATING OFFICER | Common Stock | 2,274 | $95.1 | $216,257 | ||
Sale | COATS LONNEL director | Common Stock | 9,824 | $94.87 | $932,003 | ||
Option | COATS LONNEL director | Common Stock | 1,312 | $76.24 | $100,027 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Jeffrey W. Albers J.D., M.B.A., MBA (1971) Chairman, Chief Executive Officer & Pres | $1,200,000 |
Ms. Kathryn Haviland (1976) Chief Operating Officer | $733,960 |
| Ms. Tracey L. McCain Esq. (1968) Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec. | $716,830 |
| Dr. Fouad Namouni M.D. (1969) Pres of R&D | $661,580 |
| Mr. Michael Landsittel (1972) Chief Financial Officer & Treasurer | $585,500 |
Mr. Alexis A. Borisy A.M. (1972) Co-Founder & Director | $45,000 |
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
5 Biotech Acquisition Targets To Accumulate In 2024
Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments
Blueprint Is Well-Positioned To Capitalize On ISM Market (Maintain 'Buy')
Exploring Blueprint's 'Blockbuster Opportunity' In Indolent Systemic Mastocytosis
Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now
Blueprint Medicines: A Slow But Steady Blueprint For Success
Zai Labs: Biopharma's Alibaba, But Better
-
What's the price of Blueprint Medicines stock today?
One share of Blueprint Medicines stock can currently be purchased for approximately $129.46.
-
When is Blueprint Medicines's next earnings date?
Unfortunately, Blueprint Medicines's (BPMC) next earnings date is currently unknown.
-
Does Blueprint Medicines pay dividends?
No, Blueprint Medicines does not pay dividends.
-
How much money does Blueprint Medicines make?
Blueprint Medicines has a market capitalization of 5.66B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.22% to 249.38M US dollars. Blueprint Medicines made a loss 506.98M US dollars in net income (profit) last year or -$2.68 on an earnings per share basis.
-
What is Blueprint Medicines's stock symbol?
Blueprint Medicines Corporation is traded on the NASDAQ under the ticker symbol "BPMC".
-
What is Blueprint Medicines's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Blueprint Medicines?
Shares of Blueprint Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Blueprint Medicines's key executives?
Blueprint Medicines's management team includes the following people:
- Mr. Jeffrey W. Albers J.D., M.B.A., MBA Chairman, Chief Executive Officer & Pres(age: 54, pay: $1,200,000)
- Ms. Kathryn Haviland Chief Operating Officer(age: 49, pay: $733,960)
- Ms. Tracey L. McCain Esq. Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec.(age: 57, pay: $716,830)
- Dr. Fouad Namouni M.D. Pres of R&D(age: 56, pay: $661,580)
- Mr. Michael Landsittel Chief Financial Officer & Treasurer(age: 53, pay: $585,500)
- Mr. Alexis A. Borisy A.M. Co-Founder & Director(age: 53, pay: $45,000)
-
Is Blueprint Medicines founder-led company?
Yes, Blueprint Medicines is a company led by its founder Mr. Alexis A. Borisy A.M..
-
How many employees does Blueprint Medicines have?
As Jul 2024, Blueprint Medicines employs 645 workers, which is 2% less then previous quarter.
-
When Blueprint Medicines went public?
Blueprint Medicines Corporation is publicly traded company for more then 10 years since IPO on 30 Apr 2015.
-
What is Blueprint Medicines's official website?
The official website for Blueprint Medicines is blueprintmedicines.com.
-
Where are Blueprint Medicines's headquarters?
Blueprint Medicines is headquartered at 45 Sidney Street, Cambridge, MA.
-
How can i contact Blueprint Medicines?
Blueprint Medicines's mailing address is 45 Sidney Street, Cambridge, MA and company can be reached via phone at +61 73747580.
-
What is Blueprint Medicines stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Blueprint Medicines in the last 12 months, the avarage price target is $127. The average price target represents a -1.90% change from the last price of $129.46.
Blueprint Medicines company profile:
Blueprint Medicines Corporation
blueprintmedicines.comExchange:
NASDAQ
Full time employees:
638
Industry:
Biotechnology
Sector:
Healthcare
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
45 Sidney Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001597264
ISIN: US09627Y1091
CUSIP: 09627Y109
